BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

12 Biotechs in Hong Kong's 18A Queue, and What Each Says It Will Spend the Money On

Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...

October 07, 2026 | Analysis

CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...

October 06, 2026 | News

Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other...

October 05, 2026 | News

Piramal Pharma Invests $5.3M to Expand Drug Substance Manufacturing in Canada

Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. With its investment throug...

October 01, 2026 | Analysis

Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset

Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...

September 23, 2026 | News

Novo Holdings Makes Strategic Investment in China’s Wound Care CDMO ForYou Medical

Novo Holdings, a leading global healthcare and life sciences investor, announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd...

September 14, 2026 | News

CordenPharma Invests €80M to Expand Sterile Injectable Manufacturing Capacity in Italy

CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional as...

September 11, 2026 | News

Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...

September 11, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

Ommo Technologies Raises Series A to Scale Spatial Intelligence Platform for Physical AI

VMS Group, a global alternative investment specialist, announced that its portfolio company, Ommo Technologies (Ommo), a spatial intelligence tec...

August 13, 2026 | News

Aureka Biotechnologies Raises $100M Series B to Advance AI-Driven Drug Discovery

Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and ...

August 12, 2026 | News

Pathos AI Secures Up to $2.2 Billion Global Licensing Deal for Alphamab's First-in-Class Bispecific ADC

Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Al...

August 06, 2026 | News

IMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand

IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharm...

August 03, 2026 | News

Eppendorf to Invest EUR 40 Million in New Penang Manufacturing Facility

Eppendorf has signed an agreement for a new production site in Penang, Malaysia, marking the start of its planned greenfield manufacturing facility in Band...

July 30, 2026 | News

Stay Connected